SHANGHAI – JW Biotechnology (Shanghai) Co. Ltd., a recently formed joint venture (JV) between Juno Therapeutics Inc. and Wuxi Apptec, will continue to develop CAR T treatments for Chinese patients, taking into account the learnings from the halted trials in the U.S. that resulted after three patient deaths.